The U.S. Food and Drug Administration approved an oral therapy from Bristol Myers Squibb for patients with advanced multiple myeloma. The medication will be marketed under the brand name Zenbexus and represents the debut of a new class of blood-cancer drugs called CELMoDs.
The approval marks a regulatory milestone for Bristol and for the myeloma treatment landscape, introducing an oral option derived from a research program focused on more potent modulators of targeted protein degradation.
CELMoDs are a class of investigational agents designed to redirect a cell’s intrinsic protein-degradation machinery to target and eliminate proteins that drive cancer. Zenbexus is part of Bristol’s effort to develop these more potent modulators for blood cancers.
The article describes CELMoDs as working by harnessing cellular processes to degrade cancer-causing proteins, a mechanism distinct from many traditional cytotoxic or targeted therapies.
Zenbexus is notable not only as the first U.S.-approved CELMoD but also as the first drug cleared by U.S. regulators using a more sensitive measure of remission. The source emphasizes that U.S. regulators used this more sensitive remission metric in granting approval, a procedural detail that signals evolving endpoints and assessment tools in hematologic oncology approvals.
The approval therefore carries both therapeutic and regulatory significance: it introduces a new mechanism of action into clinical practice while reflecting an expanded use of sensitive disease measures in FDA decision making.
Separately, a U.S. appeals court ruled that a lower-court judge erred in dismissing a $6.7 billion lawsuit against Bristol Myers Squibb. The suit alleges that Bristol cheated former Celgene shareholders by delaying federal approval for three drugs tied to contingent payments.
In a unanimous 3-0 decision, the appeals court concluded that the trustee designated to represent Celgene shareholders, UMB Bank, was entitled to serve despite an error in its appointment. That determination revived the litigation and allows the shareholders’ claims to proceed.
The litigation arises from Bristol Myers Squibb’s 2019 acquisition of Celgene for $80.3 billion. As part of the transaction, certain Celgene shareholders received contingent value rights (CVRs): contractual entitlements to an additional $9 per share in cash if Bristol secured timely U.S. regulatory approvals for three defined drugs.
Plaintiffs in the case contend that Bristol’s conduct delayed federal approvals for those drugs and thereby deprived Celgene shareholders of the CVR-related payments. The appeals court’s ruling focused on the procedural question of whether UMB Bank could represent shareholder interests as trustee; it determined the appointment error did not bar the trustee from litigating on behalf of the CVR holders.
The revived suit exposes Bristol to potential liability tied to billions in contingent payments and keeps scrutiny on the corporate and regulatory timeline surrounding the post-acquisition drug approvals. For former Celgene shareholders, the appeals court ruling preserves a pathway to pursue the alleged financial harms related to delayed approvals.
For the broader biopharma sector, the litigation highlights how acquisition agreements that rely on regulatory milestones can produce protracted disputes when approvals do not align with contractual timelines. The case underscores the financial and legal risks companies assume when they structure deals with CVR-based contingencies.
The source does not report additional procedural dates, specific trial schedule details, or predicted outcomes; those items were not provided in the article.
The article references related STAT+ coverage, including an exclusive about a controversial drug-testing lab suing the organization that develops drug standards. That coverage and the remainder of the detailed Pharmalot column are behind the STAT+ paywall, and the source indicates full access requires a STAT+ subscription.